Probiotic modulation of gut microbiota by Bacillus coagulans MTCC 5856 in healthy subjects: A randomized, double-blind, placebo-control study
Background: Probiotics are known to rebalance the gut microbiota in dysbiotic individuals, but their impact on the gut microbiome of healthy individuals is seldom studied. The current study is designed to assess the impact and safety of Bacillus coagulans (Weizmannia coagulans) microbial type cultur...
Saved in:
Published in | Medicine (Baltimore) Vol. 102; no. 20; p. e33751 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hagerstown, MD
Lippincott Williams & Wilkins
19.05.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background:
Probiotics are known to rebalance the gut microbiota in dysbiotic individuals, but their impact on the gut microbiome of healthy individuals is seldom studied. The current study is designed to assess the impact and safety of Bacillus coagulans (Weizmannia coagulans) microbial type culture collection 5856 (LactoSpore®) supplementation on microbiota composition in healthy Indian adults.
Methods:
The study participants (N = 30) received either LactoSpore (2 billion colony-forming units/capsule) or placebo for 28 days. The general and digestive health were assessed through questionnaires and safety by monitoring adverse events. Taxonomic profiling of the fecal samples was carried out by 16S rRNA amplicon sequencing using the Illumina MiSeq platform. The bacterial persistence was enumerated by quantitative reverse transcription-polymerase chain reaction.
Results:
Gut health, general health, and blood biochemical parameters remained normal in all the participants. No adverse events were reported during the study. Metataxonomic analysis revealed minimal changes to the gut microbiome of otherwise healthy subjects and balance of Bacteroidetes and Firmicutes was maintained by LactoSpore. The relative abundance of beneficial bacteria like Prevotella, Faecalibacterium, Blautia, Megasphaera, and Ruminococcus showed an increase in probiotic-supplemented individuals. The quantitative polymerase chain reaction analysis revealed highly variable numbers of B. coagulans in feces before and after the study.
Conclusion:
The present study results suggest that LactoSpore is safe for consumption and does not alter the gut microbiome of healthy individuals. Minor changes in a few bacterial species may have a beneficial outcome in healthy individuals. The results reiterate the safety of B. coagulans microbial type culture collection 5856 as a dietary supplement and provide a rationale to explore its effect on gut microbiome composition in individuals with dysbiosis. |
---|---|
Bibliography: | Received: 1 February 2023 / Received in final form: 20 March 2023 / Accepted: 12 April 2023 The authors have no funding to disclose. The authors MM, KN, SP, LM, and SA are affiliated with Sami-Sabinsa Group Limited or Sabinsa Corporation. The remaining authors have no conflicts of interest to disclose. Supplemental Digital Content is available for this article. All data generated or analyzed during this study are included in this published article [and its supplementary information files]. The trial was registered prospectively on the Clinical Trial Registry of India (CTRI) with the registration number CTRI/2018/10/015913. How to cite this article: Majeed M, Nagabhushanam K, Mundkur L, Paulose S, Divakar H, Rao S, Arumugam S. Probiotic modulation of gut microbiota by Bacillus coagulans MTCC 5856 in healthy subjects: A randomized, double-blind, placebo-control study. Medicine 2023;102:20(e33751). * Correspondence: Sivakumar Arumugam, Sami-Sabinsa Group Limited, 19/1 and 19/2, First Main, Second Phase, Peenya Industrial Area, Bangalore, Karnataka 560058, India (e-mail: sivakumar@sami-sabinsagroup.com). ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
ISSN: | 0025-7974 1536-5964 1536-5964 |
DOI: | 10.1097/MD.0000000000033751 |